Holen Sie sich die Stockscreener-App
4.22
0.97%
0.08
Galectin Therapeutics Inc Aktie (GALT) Neueste Nachrichten
Galectin Therapeutics Stock Price Forecast. Should You Buy GALT? - StockInvest.us
Galectin Therapeutics (NASDAQ:GALT): Can Momentum Outrun Weak Results? - Kalkine Media
Galectin Therapeutics (NASDAQ:GALT) Shares Pass Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Galectin Therapeutics Inc. (GALT) Peer Comparison – Compare with Others - Value Research
Galectin Therapeutics Inc. (GALT) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Galectin Therapeutics (NASDAQ:GALT): Is Momentum Turning Stronger? - kalkinemedia.com
Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above 200-Day Moving AverageHere's What Happened - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Galectin Therapeuti - The National Law Review
Galectin (GALT) EPS and Revenue: EPS Misses Its Estimate; Trading Move: The Stock Loses 0.63% in the Available RecordUpward Estimate Revision - vinanet.vn
Galectin (GALT) Earnings Update: Profit Per Share Falls Below Its Benchmark in the Reported Period; Market Response - vinanet.vn
HC Wainwright Analysts Lift Earnings Estimates for GALT - MarketBeat
Galectin Therapeutics (GALT) Holds Gains at $3.49 After 1.45% Advance — Key Levels in FocusSuperTrend Flip - vinanet.vn
H.C. Wainwright Maintains Galectin Therapeutics(GALT.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Form 8K Galectin Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria
Galectin Therapeutics (NASDAQ:GALT) Issues Quarterly Earnings Results - MarketBeat
Galectin Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Galectin Therapeutics Q2 Results: EPS misses estimate, losses widen - scanx.trade
Galectin Therapeutics Q2 Net Loss Widens to $9.1M as Derivative Charges Rise - Minichart
Is Galectin Therapeutics Inc (GALT) Overvalued After Q2 Earnings Miss? GF Score: 22/100 - GuruFocus
Galectin Therapeutics Reports June 30, 2026 Financial Results - TradingView
Galectin Therapeutics reports Q2 2026 net loss $9.2M, cash $13.3M, submits Phase 3 protocol - TradingView
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update - marketscreener.com
Galectin Reports $9.1 Million Q2 Net Loss and FDA Phase 3 Agreement - Quiver Quantitative
Galectin Therapeutics、2026年6月30日決算の結果を発表し、事業状況を更新 - Moomoo
GALT Q2'26 Earnings: EPS estimate is (0.09) USD - TradingView
Galectin Therapeutics (NASDAQ:GALT) Upgraded to Hold at Zacks Research - MarketBeat
Galectin Therapeutics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
Galectin Therapeutics Inc. (GALT) Investigation: Bronstein, Gewir - The National Law Review
Galectin Therapeutics (GALT) Jumps 7% to $3.45: Biotech Breakout Gains MomentumSentiment Shift - vinanet.vn
Galectin Therapeutics (GALT) Advances 2.48% to $3.3, Holds Above Key Support LevelLiquidity Order Flow - dars.gov.et
Galectin Therapeutics (GALT) Holds Steady at $3.10 as Shares Trade Within Tight RangeDebt Free Companies - dars.gov.et
Galectin Therapeutics (GALT) Projected to Announce Quarterly Earnings on Thursday - MarketBeat
Galectin Therapeutics strengthens balance sheet via debt-to-equity conversion - The Globe and Mail
Galectin chairman converts $105.8 million debt to equity By Investing.com - Investing.com India
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Galectin chairman converts $105.8 million debt to equity - Investing.com
Richard Uihlein converts GALT debt into 34,376,167 new shares - Stock Titan
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Common Stock by Chairman Richard E. Uihlein - Quiver Quantitative
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet - 富途牛牛
Galectin Therapeutics (GALT) director converts credit notes into stock - Stock Titan
Galectin Therapeutics Converts $105.8M Debt into Equity Shares - kalkinemedia.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Galectin Ther - The National Law Review
Galectin Therapeutics (GALT) Slides 8% as Small-Cap Biotech Selling Pressure IntensifiesEarnings Miss Risk - dars.gov.et
Galectin Therapeutics (GALT) Drops 8% as Shares Approach Key Support at $2.82Spring Pattern - vinanet.vn
Galectin Therapeutics Inc. Revenue Breakdown – NASDAQ:GALT - TradingView
Galectin Therapeutics Inc (GALT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Galectin Therapeutics Inc (GALT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Galectin Therapeutics Inc (GALT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Galectin Therapeutics Inc (GALT) Cash Flow - tradingkey.com
Galectin Therapeutics Inc (GALT) Institutional Confidence - TradingKey
GALT|Galectin Therapeutics Inc|Price:3.470|Chg%:+0.020 - TradingKey
TradingKey - TradingKey
GALT|Galectin Therapeutics Inc|Price:3.390|Chg%:-0.080 - TradingKey
Galectin Therapeutics (NASDAQ:GALT) Breaks a Key Trend Line - Kalkine Media
GALT stock reacts to Galectin Therapeutics Q1 2026 cash position and R&D progress - Ad-hoc-news.de
Galectin Therapeutics (NASDAQ:GALT) Stock Passes Above 200-Day Moving AverageHere's Why - MarketBeat
GALT stock gains support as Galectin Therapeutics keeps cash focus - Ad-hoc-news.de
Form 4 Galectin Therapeutics Inc For: 16 July By Investing.com - Investing.com Nigeria
Galectin Therapeutics CMO Jamil Khurram sells $83,284 in stock - Investing.com
Galectin Therapeutics (GALT) CMO sells 16,250 shares under 10b5-1 plan - Stock Titan
Can Galectin Therapeutics (NASDAQ:GALT) Regain Confidence? - Kalkine Media
Galectin Therapeutics (NASDAQ:GALT) Stock Rating Lowered by Zacks Research - MarketBeat
1.30%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):